Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.
The expression of the oncogene products ras p21, c-myc and the growth factor EGF (epidermal growth factor) was studied immunohistochemically in the tissue of 119 benign and malignant human breasts. In most cases, histologically normal breast tissues and benign lesions were found to be negative or poorly-expressive for reactivity with each antibody. Similar findings were observed in carcinoma in situ. Invading breast carcinomas demonstrated a significantly higher percentage of stained cells than that observed in benign lesions or carcinoma in situ; forty-two of 66 invasive breast carcinomas (63.6%) were highly-expressive for ras p21, thirty-eight (57.6%) for c-myc and twenty (30.3%) for EGF, but overall correlations between each oncogene expression and the clinical stage, tumor size or degree of differentiation were not found. The overall 5-year survival rate was studied in 58 patients with Stage II and III in association with each oncogene or EGF expression. Their survival rate was significantly effected by the EGF expression (0.05 less than p less than 0.1) but not by ras p21 or c-myc expression. Analysis of 36 specimens available with ER (estrogen-receptor) level revealed a significant correlation between the ER status and c-myc or E2 (estradiol) and a significant inverse correlation between ER status and ras p21 or EGF expression (P less than 0.05). The expression of ras p21, EGF and c-myc was not associated with metastatic tumor progression.
Mizukami
Y
Y
Pathology Section, Kanazawa, University Hospital, Japan.
Nonomura
A
A
Noguchi
M
M
Taniya
T
T
Koyasaki
N
N
Saito
Y
Y
Hashimoto
T
T
Matsubara
F
F
Yanaihara
N
N
D000906:Antibodies; D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology*; D002278:Carcinoma in Situ / Q000235:genetics / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000235:genetics / Q000473:pathology; D004815:Epidermal Growth Factor / Q000032:analysis / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D016259:Genes, myc; D011905:Genes, ras; D006801:Humans; D009367:Neoplasm Staging; D011379:Prognosis; D016271:Proto-Oncogene Proteins c-myc / Q000032:analysis*; D016283:Proto-Oncogene Proteins p21(ras) / Q000032:analysis*; D012189:Retrospective Studies
D000906:Antibodies; D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D016271:Proto-Oncogene Proteins c-myc; D004815:Epidermal Growth Factor; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)